A Case-Based Examination on Preventing Neutropenic Complications

Release Date: September 27, 2006
Expiration Date: September 26, 2007

Target Audience
Physicians involved in the care of patients with cancer.

Statement of Need
Physicians who care for patients with cancer need the most current information on cancer care. Utilization of granulocyte stimulating factor (GSF) as outlined in the NCCN Guidelines can reduce the incidence of febrile neutropenia. This activity will discuss the appropriate use of GSF in accordance with these guidelines. It will also emphasize the importance of administration in the first cycle of chemotherapy.

Educational Objectives
Upon completion of this activity, participants should be able to improve their patient care by being able to:

• Discuss the incidence of febrile neutropenia to have a better understanding of its frequency.
• Verify the importance of administering GSF in the first cycle of chemotherapy to reduce the risk of febrile neutropenia.
• According to NCCN Guidelines, outline the appropriate utilization of GSF in febrile neutropenia.

Faculty Information

Michael E. Rader, MD Clinical Assistant Professor of Medicine Columbia University College of Physicians and Surgeons Director, Union State Bank Cancer Center at Nyack Hospital Nyack, New York

Accreditation

Physicians
Creative Educational Concepts, Inc. is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Creative Educational Concepts, Inc. designates this educational activity for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Instructions
To receive credit for this activity, you must:

• Review the full content of the activity and reflect on its teaching.
• Successfully complete the post-test with a minimum grade of 80% or higher.
• You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion and submission of the post-test and evaluation.

Fee
There is no fee for this activity.

Creative Educational Concepts, Inc. has no relevant financial relationship with any commercial interests related directly or indirectly to the content of this educational activity.

Michael Rader, MD has disclosed that he is a consultant and on the speakers' bureau for Amgen Inc.

It is the policy of the accreditors to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing medical education activities.

Unlabeled Use Disclosure
The author and sponsor of this continuing medical education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g. their administration, dosages, contraindications, adverse reactions, interactions, special warning, precautions) and drug delivery systems is subject to change; however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery system.

The faculty has indicated that there will be discussion of unlabeled/unapproved use of products during the presentation.

Commercial Support
This activity is supported by an educational grant from Amgen Inc.

Software Requirements
Flash Player Plugin(v7.0.1.9 or greater)
Adobe Acrobat Reader
Internet Explorer 5.5 or Firefox
Internet Explorer is not supported on the Macintosh.
Windows 2000 or above
Mac OS 10.2.8

Continue